Disruptive Growth & Healthcare Conference
February 15-16
New York City
The Disruptive Growth & Healthcare Conference will feature healthcare companies focusing on innovations to meet on unmet medical needs, as well as growth companies with disruptive technologies and business models. The audience is more than 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, RHK representatives and their clients – all of whom recognize the tremendous opportunities of disruptive ideas and their infinite potential at market introduction. For more information visit www.DisruptNYC.com
Presenting Companies
Acme United (ACU)
Acme United (NYSE: ACU) an innovative supplier of cutting devices and safety products for school, home, office, hardware and industrial use. Its leading brands include Westcott®,a major brand for scissors and rulers; Clauss®, which primarily manufactures cutting instruments for professionals in the hardware & industrial, lawn & garden, food processing, sewing and housewares markets; Camillus®, a recognizable brand in the knife industry; fishing gear brand CUDA®; DMT, a manufacturer of large diamond grinding and polishing wheels for industrial application; as well as First Aid Only®, PhysiciansCare® and Pac-Kit®. The company has operations in the United States, Canada, Europe (located in Germany) and Asia (located in Hong Kong and China). For more information, visit the company's website at www.acmeunited.com.
Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals (NYSE: ATNM) is a biopharmaceutical company developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The company's radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target. For more information, visit the company's website at www.actiniumpharma.com.
Aeterna Zentaris (AEZS)
Aeterna Zentaris (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing and commercializing Zoptrex™, a novel cytotoxic compound. To ensure development, registration and launch of the product, the company intends to license out certain commercial rights to Zoptrex™. The company also actively seeks opportunities to in-license and acquire products for U.S. commercialization. For more information, visit the company's website at www.aezsinc.com.
Arch Therapeutics (ARTH)
Arch Therapeutics (OTCQB: ARTH) is a biotech company developing an innovative, elegant and superior approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, "stasis and barrier applications." For more information, visit the company's website at www.archtherapeutics.com.
AudioEye (AEYE)
AudioEye (OTC: AEYE) provides web accessibility solutions to Internet, print, broadcast and other media to people in the United States. The company's solutions are designed to build accessibility into existing website or web applications; quickly conform to ADA-related standards and best practices; outsource burden of accessibility in time and money-saving manners; and to bridge the gap until accessibility issues can be fixed at the source. The AudioEye Digital Accessibility Platform is designed to be the developer's comprehensive web accessibility tool. This tool empowers auditors, designers, and developers to understand issues of accessibility and improve website infrastructure through the use of an innovative and easy-to-use interface. For more information, visit the company's website at www.audioeye.com.
Bridgeline Digital (BLIN)
Bridgeline Digital (NASDAQ: BLIN), The Digital Engagement Company™, helps customers to maximize the performance of their mission critical websites, intranets and online stores. The company's iAPPS platform deeply integrates web content management, eCommerce, eMarketing, social media management, and web analytics to help marketers deliver digital experiences that attract, engage and convert their customers across all channels. Headquartered in Burlington, Massachusetts, Bridgeline has thousands of quality customers that range from small- and medium-sized organizations to Fortune 1000 companies. For more information, visit the company's website at www.bridgelinedigital.com.
Cancer Genetics (CGIX)
Cancer Genetics (NASDAQ: CGIX) develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. The company's tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biopharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. For more information, visit the company's website at www.cancergenetics.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is engaged in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate currently being evaluated in a phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. For more information, visit the company's website at www.cellectar.com.
ChineseInvestors.com (CIIX)
ChineseInvestors.com (OTCQB; CIIX), headquartered in Los Angeles, with offices in New York City and Shanghai China, engages in providing a wide range of products, services and information for the global Chinese population. Founded in 1999, CIIX endeavors to be an innovative company providing (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) support services to various partners; (c) consultative services to smaller private companies considering becoming a public company; (d) advertising and public relation related support services; and (e) other services we may identify having the potential to create value or partnership opportunity with our existing services. For more information, visit the company's website at www.Chinesefn.com.
Ener-Core (ENCR)
Ener-Core (OTC: ENCR) designs, develops and manufactures products that are based on power oxidizer technologies. The company's proprietary technology provides an alternative to traditional methods of destroying gaseous pollution by enabling industrial facilities to generate on-site power from their waste gases. Its products include Ener-Core PowerStation EC250 and Ener-Core Powerstation KG2-3G/GO, which have applications in landfills, distilleries, and wastewater treatment plants, as well as various industrial processes. For more information, visit the company's website at www.ener-core.com.
Enzo Biochem (ENZ)
Enzo Biochem (NYSE: ENZ) is an integrated life science and biotechnology company engaged in the R&D, manufacture and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, which provides routine and esoteric clinical laboratory tests or procedures used in general patient care to establish or support a diagnosis; Life Sciences, which manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers; and Therapeutics, which is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. For more information, visit the company's website at www.enzo.com.
KaloBios Pharmaceuticals (KBIO)
KaloBios Pharmaceuticals (OTC: KBIO) develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, other brain cancers in children, and rare hematologic cancer indications. For more information, visit the company's website at www.kalobios.com.
Live Ventures (LIVE)
Live Ventures (NASDAQ: LIVE) is a diversified growth holding company with a strategic focus on acquiring United States-based middle market growth manufacturing and value-add distribution companies. The company operates several wholly owned subsidiaries and has a strategic focus on acquiring profitable companies that have demonstrated a strong history of earnings power. Live Ventures provides, among other businesses, marketing solutions that boost customer awareness and merchant visibility on the Internet. For more information, visit the company's website at www.live-ventures.com.
Relmada Therapeutics (RLMD)
Relmada Therapeutics (NYSE: RLMD) is a clinical-stage biotechnology company focused on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER for the management of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence indications; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. For more information, visit the company's website at www.relmada.com.
Rexahn Pharmaceuticals (RNN)
Rexahn Pharmaceuticals (NYSE: RNN) is a clinical stage biopharmaceutical company that discovers, develops, and commercializes treatments for cancer. The company's clinical stage oncology candidates include Archexin that completed a pilot phase II a clinical trial for the treatment of pancreatic cancer; RX-3117, which is in phase I b clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. For more information visit the company's website at www.rexahn.com.
RXi Pharmaceuticals (RXII)
RXi Pharmaceuticals (NASDAQ: RXII) is a clinical-stage RNAi company that focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. Its clinical development programs include RXI-109, a self-delivering RNAi compound in phase IIa clinical trial for prevention or reduction of dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids, and in a phase I/II clinical trial in retinal scarring. RXi is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, in phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. For more information, visit the company's website at www.rxipharma.com.
Spring Bank Pharmaceuticals (SBPH)
Spring Bank Pharmaceuticals (OTC: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body's immune response to viral infections. For more information, visit the company's website at www.springbankpharm.com.
Xplore Technologies (XPLR)
Xplore Technologies (NASDAQ: XPLR) develops, integrates, and markets rugged mobile personal computer systems (PCs) in the United States, Canada, and internationally. The company's products enable the extension of traditional computing systems to a range of field personnel, including energy pipeline inspectors, public safety personnel, warehouse workers, and pharmaceutical scientists. It offers a line of iX104 tablet PCs that are designed to operate in various work environments, such as extreme temperatures, constant vibrations, rain, and blowing dirt and dusty conditions; and are fitted with a range of performance matched accessories. For more information, visit the company's website at www.xploretech.com.
